Treatment of Giant cell arteritis: focus on upadacitinib

Key Points

• This research aims to evaluate the effectiveness of upadacitinib in treating giant cell arteritis (GCA) compared to tocilizumab.
• Compared the effectiveness of upadacitinib and tocilizumab in treating patients with GCA.
• Assessed glucocorticoid use and related toxicity in patients receiving upadacitinib.
• Measured inflammatory markers to evaluate the treatment effects.
• Upadacitinib significantly reduces the need for glucocorticoids compared to tocilizumab.
• Patients on upadacitinib experience lower risks of glucocorticoid-related toxicity.
• Inflammatory marker suppression is less pronounced with upadacitinib than with tocilizumab.